---
title: "After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296918567.md"
description: "After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)"
datetime: "2026-08-25T13:00:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296918567.md)
  - [en](https://longbridge.com/en/news/296918567.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296918567.md)
generator: "portal-rs"
---

# After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [How Cathie Wood's fund gave us a back door to Moderna's breakthrough](https://longbridge.com/en/news/298769510.md)
- [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md)
- [Promising Biotech Stocks To Keep An Eye On - September 12th](https://longbridge.com/en/news/298811794.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**